ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2254

Association of disease activity with insomnia, depression, and fatigue in patients with rheumatoid arthritis: a multicenter prospective observational study

Misako Higashida-Konishi1, Keisuke Izumi2, Shuntaro Saito Saito3, Hiroki Tabata4, Satoshi Hama4, Tatsuhiro Oshige4, Yutaka Okano4, Hisaji Oshima4, Katsuya Suzuki4, Jiro Sakamoto5, Toshikazu Fukami5, Kazumichi Minato5, Nobuhiko Kajio6, Yasushi Kondo3, Hiroaki Taguchi6 and Yuko Kaneko3, 1NHO Tokyo Medical Center, Tokyo Meguroku, Japan, 2Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center/Keio University School of Medicine/TechDoctor, Inc., Tokyo, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 4Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center, Tokyo, Japan, 5TechDoctor, Inc., Tokyo, Japan, 6Department of Rheumatology, Kawasaki Municipal Hospital, Kanagawa, Japan

Meeting: ACR Convergence 2025

Keywords: depression, Disease Activity, Fatigue, rheumatoid arthritis, sleep

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with rheumatoid arthritis (RA) often experience not only joint-related symptoms but also systemic issues such as insomnia, depression, and fatigue [1–3]. These symptoms may persist despite therapeutic advances and significantly impair quality of life [1]. This study aimed to clarify the prevalence of insomnia, depression, and fatigue in RA and examine their relationship with disease activity.

Methods: This prospective study enrolled RA patients who could respond to a structured questionnaire. Insomnia was assessed using the Athens Insomnia Scale (AIS), depressive symptoms were evaluated via the Patient Health Questionnaire-9 (PHQ-9), and fatigue was measured using both the Brief Fatigue Inventory (BFI) and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Disease activity of RA was measured by the Disease Activity Score in 28 joints with CRP (DAS28-CRP), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Functional status of RA was determined through the Health Assessment Questionnaire-Disability Index (HAQ-DI). All patients met the 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria [4] for RA.

Results: A total of 107 RA patients (90 female, 17 male) participated, with a mean age of 55 years and a mean disease duration of 82 months. The median DAS28-CRP was 2.9, CDAI was 10.2, SDAI was 10.2, and HAQ-DI was 0.5. Insomnia was reported in 85% of participants, and the AIS score was significantly associated with DAS28-CRP (r=0.22, p=0.03), CDAI (r=0.23, p=0.03), SDAI (r=0.22, p=0.03), and HAQ-DI (r=0.22, p=0.03). Depression was reported in 13% of participants, and the PHQ-9 score was significant associations with DAS28-CRP (r=0.34, p< 0.01), CDAI, (r=0.34, p< 0.01) and SDAI (r=0.34, p< 0.01). Severe fatigue was also reported in 85% of participants, with BFI scores significantly correlated with DAS28-CRP (r=0.43, p< 0.01), CDAI (r=0.35, p< 0.01), SDAI (r=0.37, p< 0.01), and HAQ-DI (r=0.31, p< 0.01). FACIT-F scores showed inverse correlations with DAS28-CRP (r=0.47, p< 0.01), CDAI (r=0.42, p< 0.01), SDAI (r=0.43, p< 0.01), and HAQ-DI (r=0.25, p=0.01). In addition, the components of disease activity assessment, especially the patient global visual analogue scale, were correlated with AIS (r=0.32, p< 0.01), PHQ-9 (r=0.40, p< 0.01), FACIT-F (r=0.45, p< 0.01), and BFI (r=0.42, p< 0.01).

Conclusion: Insomnia and fatigue were highly prevalent among RA patients, affecting over 80% of patients, while depression was identified in 13%. All symptoms showed associations with disease activity and functional impairment. These findings suggest that optimal RA management should also address psychological and fatigue-related symptoms. References: [1] Latocha KM et al. Rheumatology (Oxford). 2023;62:1097-1107.[2] Kwiatkowska B et al. Psychol Health Med. 2019;24:333-343.[3] Pope JE. RMD Open. 2020;6:e001084.[4] Aletaha D et al. Arthritis Rheum. 2010;62:2569-81. Acknowledgement: M HK and KI are contributed equally.


Disclosures: M. Higashida-Konishi: Chugai, 6; K. Izumi: Abbvie, 6, Asahi Kasei, 6, Chugai, 6, Eisai, 6, Gilead Sciences, 6, TechDoctor, Inc, 4, Teijin Pharma, 6; S. Saito: None; H. Tabata: None; S. Hama: None; T. Oshige: None; Y. Okano: None; H. Oshima: None; K. Suzuki: AbbVie, 6, Asahi Kasei, 5, 6, Boehringer-Ingelheim, 6, Chugai, 6, Eisai, 6, Eli Lilly, 6, Gilead, 6, GlaxoSmithKline, 6, Mitsubishi Tanabe, 6, Pfizer, 6, Sanofi, 6, Taisho, 6, UCB, 6, Viatris, 6; J. Sakamoto: None; T. Fukami: None; K. Minato: None; N. Kajio: None; Y. Kondo: None; H. Taguchi: None; Y. Kaneko: AbbVie/Abbott, 6, Asahi Kasei, 5, 6, Chugai, 5, 6.

To cite this abstract in AMA style:

Higashida-Konishi M, Izumi K, Saito S, Tabata H, Hama S, Oshige T, Okano Y, Oshima H, Suzuki K, Sakamoto J, Fukami T, Minato K, Kajio N, Kondo Y, Taguchi H, Kaneko Y. Association of disease activity with insomnia, depression, and fatigue in patients with rheumatoid arthritis: a multicenter prospective observational study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/association-of-disease-activity-with-insomnia-depression-and-fatigue-in-patients-with-rheumatoid-arthritis-a-multicenter-prospective-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-disease-activity-with-insomnia-depression-and-fatigue-in-patients-with-rheumatoid-arthritis-a-multicenter-prospective-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology